2162 — Keymed Biosciences Balance Sheet
0.000.00%
- HK$18.76bn
 - HK$16.66bn
 - CNY428.12m
 
Annual balance sheet for Keymed Biosciences, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st  | 2021 December 31st  | 2022 December 31st  | 2023 December 31st  | 2024 December 31st  | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS | 
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS | 
| Status: | Final | Final | Final | Final | Final | 
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 354 | 3,525 | 3,175 | 2,719 | 2,156 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.23 | 13.6 | 7.44 | 36.8 | 69.5 | 
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 381 | 3,582 | 3,310 | 2,940 | 2,466 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 126 | 306 | 596 | 911 | 1,075 | 
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 530 | 3,934 | 3,932 | 3,883 | 3,767 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 80.2 | 112 | 380 | 314 | 748 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1,624 | 283 | 592 | 897 | 1,292 | 
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | -1,095 | 3,651 | 3,340 | 2,986 | 2,475 | 
| Total Liabilities & Shareholders' Equity | 530 | 3,934 | 3,932 | 3,883 | 3,767 | 
| Total Common Shares Outstanding |